[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366981-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366981-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microbiome-driven-resistance-in-cervical-cancer-therapy-from-mechanistic-dissection-to-clinical-translation","Microbiome-driven resistance in cervical cancer therapy - from mechanistic dissection to clinical translation","","Cervical cancer remains a major global health burden, and 30–50% of locally advanced-stage patients develop treatment resistance despite standard therapies, resulting in recurrence and mortality. This review synthesizes evidence that the vaginal microbiome modulates therapeutic efficacy, with Lactobacillus iners enrichment and Lactobacillus crispatus depletion promoting resistance via lactate-mediated metabolic rewiring, immune checkpoint stabilization, and altered drug metabolism. Longitudinal analyses show dynamic microbiome trajectories during therapy and geographic variation, including HIV co-infection effects in sub-Saharan Africa. The review critically evaluates microbiome-based interventions, ranging from probiotics to engineered bacteria and synthetic biology-driven precision approaches, and highlights the need for standardized multicentre trial protocols that integrate mechanistic insights with clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microbiome-driven-resistance-in-cervical-cancer-therapy-from-mechanistic-dissection-to-clinical-translation/366981/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microbiome-driven-resistance-in-cervical-cancer-therapy-from-mechanistic-dissection-to-clinical-translation/366981.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is treatment resistance common in locally advanced cervical cancer?","Question",{"text":63,"@type":64},"Even with standard-of-care chemoradiotherapy, about 30–50% of locally advanced patients develop resistance, leading to persistent or recurrent disease within two years.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the microbiome contribute to resistance during cervical cancer therapy?",{"text":68,"@type":64},"Vaginal microbial dysbiosis can drive resistance through lactate-mediated metabolic rewiring, immune checkpoint stabilization, and changes in drug metabolism.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors explain variation in microbiome-driven treatment responses?",{"text":72,"@type":64},"Longitudinal microbiome trajectories differ during therapy, and geographic variation—such as HIV co-infection in sub-Saharan Africa—further modulates responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366981,1790196713,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Expert Reviews in Molecular Medicine  \n[www.cambridge.org/erm](www.cambridge.org/erm)  \nReview  \nCite this article: Wu X, Wang D, Mao X, Dong Band Wang Y (2026) . Microbiome-driven resistance in cervical cancer therapy: from mechanistic dissection to clinical translation. Expert Reviews in Molecular Medicine, 28, e2, 1–14  \n[https://doi.org/10.1017/erm.2025.10029](https://doi.org/10.1017/erm.2025.10029)  \nReceived: 20 November 2025  \nRevised: 05 December 2025  \nAccepted: 16 December 2025  \nKeywords:  \ncervical cancer; geographic variation; human immunodeficiency virus; immunotherapy; lactate metabolism; Lactobacillus; microbiome; synthetic biology; treatment resistance  \nCorresponding authors:  \nYue Wang and Binhua Dong; Emails: [392879887@fjmu.edu.cn](392879887@fjmu.edu.cn); [dongbinhua86@fjmu.edu.cn](dongbinhua86@fjmu.edu.cn)  \n© The Author(s), 2025 . Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercialShareAlike licence ([http://](http://)[ ](http://)[creativecommons.org/licenses/by-nc-sa/4.0](creativecommons.org/licenses/by-nc-sa/4.0)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press or the rights holder(s) must be obtained prior to any commercial use.  \nMicrobiome-driven resistance in cervical cancer therapy: from mechanistic dissection to clinical translation  \nXiaoqi Wu1 , Dingjie Wang2,3,4,5 , Xiaodan Mao4,5, BinHua Dong4,5  and Yue Wang3,4,5   \n1The Second Affiliated Hospital of Fujian University ofTraditional Chinese Medicine, Fuzhou, Fujian, P.R. China; 2College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, P.R. China; 3Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, P.R. China; 4Department of Gynecology, Fujian Key Laboratory of Women and Children’s Critical Diseases Research, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, P.R. China and 5Fujian Clinical Research Center for Gynecological Oncology, Fuzhou, Fujian, P.R. China  \nAbstract  \nCervical cancer remains a major global health burden. Despite standard-of-care therapies, 30– 50% of locally advanced-stage patients develop treatment resistance, leading to recurrence and mortality. While tumour-intrinsic mechanisms (e.g., DNA methylation, cancer-associated fibroblasts) explain only partial resistance heterogeneity, emerging evidence identifies the microbiome as a critical modulator of therapeutic efficacy. This review synthesizes recent advances demonstrating that vaginal microbial dysbiosis, characterized by Lactobacillus iners enrichment and L. crispatus depletion, drives resistance through lactate-mediated metabolic rewiring, immune checkpoint stabilization and drug metabolism alteration. Longitudinal studies reveal dynamic microbiome trajectories during therapy, with geographic variations (notably HIV co-infection in sub-Saharan Africa) further modulating treatment responses. We critically evaluate microbiome-based interventions, from probiotics to engineered bacteria, including synthetic biology-driven precision microbiome therapies, and establishing standardized multicentre trial protocols. Bridging mechanistic insights with clinical application represents a paradigm shift towards microbiome-informed cervical cancer management.  \nIntroduction  \nThe resistance crisis in cervical cancer  \nCervical cancer continues to pose a formidable challenge to global women’s health, with epidemiological projections indicating 700,000 annual new cases by 2030 (Ref. 1) . Cu","cbCaisjrjMS2WSXx","https://ap.wps.com/l/cbCaisjrjMS2WSXx","pdf",3710204,14,"English","# Abstract\n# Introduction\n## The resistance crisis in cervical cancer\n## The microbiome as an emerging paradigm for tumour treatment","[{\"question\":\"Why is treatment resistance common in locally advanced cervical cancer?\",\"answer\":\"Even with standard-of-care chemoradiotherapy, about 30–50% of locally advanced patients develop resistance, leading to persistent or recurrent disease within two years.\"},{\"question\":\"How does the microbiome contribute to resistance during cervical cancer therapy?\",\"answer\":\"Vaginal microbial dysbiosis can drive resistance through lactate-mediated metabolic rewiring, immune checkpoint stabilization, and changes in drug metabolism.\"},{\"question\":\"What factors explain variation in microbiome-driven treatment responses?\",\"answer\":\"Longitudinal microbiome trajectories differ during therapy, and geographic variation—such as HIV co-infection in sub-Saharan Africa—further modulates responses.\"}]","Microbiome-driven resistance in cervical cancer therapy - from mechanistic dissection to clinical translation | PDF",1790168542,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfec5c63e9b140cb7635708edd39c4ef.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ce805b4f6ffefde202783e2361d1074.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23fdb0338052b5cc113bb760e2b43256.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b10ee4edd26101ac1167936bdb4c55a.webp",980,1306]